World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
28503
World Ranking
17413
National Ranking
199

Winnie Yeo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Winnie Yeo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 380 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Winnie Yeo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Winnie Yeo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Winnie Yeo is a researcher affiliated with the Chinese University of Hong Kong in China, specializing primarily in the field of Medicine with a focus on Oncology. Their research output covers a broad range of topics related to cancer treatment, survivorship, and pharmacology, with a significant emphasis on breast cancer and associated therapies.

Their key research topics include:

  • Breast Cancer Treatment Studies
  • Cancer Risks and Factors
  • Advanced Breast Cancer Therapies
  • Nausea and vomiting management
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer survivorship and care

Winnie Yeo has published extensively in several academic venues, frequently contributing to journals such as:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Research Square (Research Square)
  • Hong Kong Medical Journal

Among their recent publications are:

  • "Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial," 2022, The Lancet
  • "HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis," 2022, BMC Medicine
  • "BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd)," 2021, Journal of Clinical Oncology
  • "Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040," 2023, Annals of Oncology
  • "Antiobesity effect of ethanolic extract of Ramulus mori in differentiated 3T3-L1 adipocytes and high-fat diet-induced obese mice," 2020, Journal of Ethnopharmacology

Frequent collaborators in their research include:

  • Frankie Mo
  • Seock-Ah Im
  • Suzanne C. Ho
  • Carol Kwok
  • Ashley Cheng

Winnie Yeo's subfields of study illustrate a diverse engagement with medical sciences, primarily through:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Surgery
  • Physiology

Best Publications

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Philip J. Johnson;Sarah Berhane;Chiaki Kagebayashi;Shinji Satomura

  • Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

    Winnie Yeo;Paul K.S. Chan;Sheng Zhong;Wing M. Ho

  • Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

    Winnie Yeo;Tung C. Chan;Nancy W.Y. Leung;Wai Y. Lam

  • A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

    Winnie Yeo;Tony S. Mok;Benny Zee;Thomas W. T. Leung

  • Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

    Anthony Tak-cheung Chan;Sing-fai Leung;Roger K.C. Ngan;Peter M.L. Teo

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy†

    Winnie Yeo;Philip J. Johnson

  • Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial

    A.T.C. Chan;P.M.L. Teo;R.K. Ngan;T.W. Leung

  • Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial

    W. Y. Lau;T. W.T. Leung;S. K.W. Ho;M. Chan

  • Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers

    Vincent Wai Sun Wong;Stephen Lam Chan;Frankie Mo;Tung Ching Chan

  • Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

    Winnie Yeo;Benny Chung-ying Zee;S. Zhong;P. K.S. Chan

  • A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.

    Anthony T.C. Chan;Peter M.L. Teo;Thomas W.T. Leung;Sing F. Leung

  • Complete Pathological Remission Is Possible with Systemic Combination Chemotherapy for Inoperable Hepatocellular Carcinoma

    Thomas W.T. Leung;Yehuda Z. Patt;Wan Yee Lau;Stephen K.W. Ho

  • High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.

    Henry Lik Yuen Chan;Chi Hang Tse;Frankie Mo;Jane Koh

  • Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy

    Winnie Yeo;Paul K.S. Chan;Wing M. Ho;Benny Zee

  • New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

    Stephen L. Chan;Frankie K.F. Mo;Philip J. Johnson;Edwin P. Hui

  • Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Sarah Berhane;Hidenori Toyoda;Toshifumi Tada;Takashi Kumada

  • Frequent p15 Promoter Methylation in Tumor and Peripheral Blood from Hepatocellular Carcinoma Patients

    I. H.N. Wong;Yuk-ming Dennis Lo;Winnie Yeo;W. Y. Lau

  • Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

    Anthony B. El-Khoueiry;Ignacio Melero;Todd S. Crocenzi;Theodore Hobart Welling

Frequent Co-Authors

Anthony T.C. Chan
Anthony T.C. Chan Chinese University of Hong Kong
Stephen L. Chan
Stephen L. Chan Chinese University of Hong Kong
Philip J. Johnson
Philip J. Johnson University of Liverpool
Tony Mok
Tony Mok Chinese University of Hong Kong
Paul B.S. Lai
Paul B.S. Lai Chinese University of Hong Kong
Paul K.S. Chan
Paul K.S. Chan Chinese University of Hong Kong
Bruno Sangro
Bruno Sangro University of Navarra
Benny Chung-ying Zee
Benny Chung-ying Zee Chinese University of Hong Kong
Masatoshi Kudo
Masatoshi Kudo Kindai University
Anthony W.H. Chan
Anthony W.H. Chan Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens the door to many online degree options that can advance your education and professional growth. If you’re considering leadership roles within healthcare, understanding the cost of mha degree programs is essential. Affordability and financial planning are key factors when choosing a path in healthcare administration.

For registered nurses aiming for the highest level of clinical practice, the best online bsn to dnp programs offer advanced, flexible ways to reach a Doctor of Nursing Practice degree. Similarly, pharmacists can expand their scope with online pharmd programs that emphasize both affordability and convenience.

Beyond clinical roles, the growing field of health data offers new opportunities. Earning a health information management bachelor degree online can pave the way for in-demand roles in healthcare systems, insurance, and data analysis. Each pathway comes with its own admission requirements, costs, and career possibilities—making it vital to research and select the online program that aligns best with your goals.

Best Scientists Citing Winnie Yeo

Trending Scientists

Recently Published Articles